Overview

Erlotinib and Sunitinib in NSCLC

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

- To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). - To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.

Phase:

Phase 1

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborators:

Genentech, Inc.
Pfizer

Treatments:

Erlotinib Hydrochloride
Sunitinib